Regulatory Shifts May Play a Role If the FDA broadens the approved use of GLP-1s or legislation changes how weight-loss drugs are classified for insurance purposes, employer decisions may shift accordingly
Previous studies have shown a potential link between GLP-1 use and non-arteritic anterior ischemic optic neuropathy (NAION), an eye condition that can cause vision loss
These medications offer a modern solution that targets both appetite regulation and metabolic processes, potentially leading to significant weight loss for certain individuals
This pattern differs from weight loss, which continues improving with dose escalation through the studied range
Ill also give recommendations for those who are taking or are considering taking them for weight loss
So thyroid hormone is made from the amino acid tyrosine, which you get from the protein in the food that you eat, and then you add iodine to it